News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,632 Results
Type
Article (39055)
Company Profile (279)
Press Release (646298)
Section
Business (203874)
Career Advice (1991)
Deals (35364)
Drug Delivery (85)
Drug Development (80803)
Employer Resources (168)
FDA (16090)
Job Trends (14805)
News (344562)
Policy (32440)
Tag
Academia (2530)
Alliances (49095)
Alzheimer's disease (1229)
Approvals (16024)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1085)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (234)
Clinical research (64249)
Collaboration (388)
Compensation (200)
COVID-19 (2531)
C-suite (94)
Data (1126)
Diabetes (152)
Diagnostics (6139)
Earnings (84821)
Employer resources (146)
Events (109482)
Executive appointments (310)
FDA (16628)
Funding (351)
Gene therapy (178)
GLP-1 (576)
Government (4326)
Healthcare (18670)
Infectious disease (2616)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3624)
Job search strategy (1417)
Layoffs (412)
Legal (7854)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19142)
Metabolic disorders (401)
Neuroscience (1504)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1480)
Obesity (231)
Opinion (179)
Patents (102)
People (56272)
Phase I (19955)
Phase II (28305)
Phase III (21097)
Pipeline (458)
Postmarket research (2553)
Preclinical (8494)
Radiopharmaceuticals (236)
Rare diseases (219)
Real estate (5890)
Regulatory (21524)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1301)
Startups (3562)
United States (13474)
Vaccines (548)
Weight loss (167)
Date
Today (133)
Last 7 days (728)
Last 30 days (3734)
Last 365 days (35651)
2024 (32712)
2023 (40074)
2022 (51173)
2021 (55714)
2020 (54088)
2019 (46541)
2018 (35021)
2017 (32109)
2016 (31480)
2015 (37555)
2014 (31318)
2013 (26348)
2012 (28570)
2011 (29267)
2010 (27329)
Location
Africa (713)
Arizona (192)
Asia (37133)
Australia (6058)
California (3325)
Canada (1293)
China (248)
Colorado (146)
Connecticut (152)
Europe (79511)
Florida (460)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2608)
Michigan (157)
Minnesota (273)
New Jersey (954)
New York (961)
North Carolina (701)
Northern California (1480)
Ohio (139)
Pennsylvania (844)
South America (1091)
Southern California (1301)
Texas (463)
Utah (90)
Washington State (361)
685,632 Results for "shionogi inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.
April 30, 2024
·
9 min read
Business
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announced the companies have completed an exclusive worldwide license agreement for the rights to MZE001, an investigational oral glycogen synthase 1 inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.
May 10, 2024
·
6 min read
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
Shionogi & Co., Ltd. announced the company is responding to the urgent global need for additional antimicrobial research and development by establishing its first discovery laboratory in the U.S., in San Diego, California.
June 3, 2024
·
9 min read
Business
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
February 26, 2024
·
7 min read
Press Releases
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
October 1, 2024
·
5 min read
Business
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of Ramón Polo, MBA, PharmD, Ph.D. as Senior Vice President, Head of Regulatory Affairs.
February 5, 2024
·
4 min read
Drug Development
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
February 27, 2024
·
10 min read
Deals
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.
June 26, 2023
·
7 min read
Pharm Country
IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease
Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced the upcoming presentation of new data at IDWeek 2023 on its investigational oral antiviral for COVID-19, ensitrelvir, and Fetroja®, an antibiotic marketed under the brand name Fetcroja® in Europe.
September 7, 2023
·
7 min read
Drug Development
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first peer-reviewed publication of the Phase 3 portion of its pivotal, double-blind, randomized, placebo-controlled Phase 2/3 study (SCORPIO-SR) in patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam in JAMA Network Open.
February 9, 2024
·
11 min read
1 of 68,564
Next